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Abstract We studied costs of healthcare and productivity
loss in 487 German outpatients starting anthroposophic
treatment: Group 1 was treated for depression, Group 2 had
depressive symptoms but were treated for another chronic
disorder, while Group 3 did not have depressive symptoms.
Costs were adjusted for socio-demographics, comorbidity,
and baseline health status. Total costs in groups 1–3
averaged €7,129, €4,371, and €3,532 in the pre-study year
(P = 0.008); €6,029, €3,522, and €3,353 in the ﬁrst year
(P = 0.083); and €4,929, €3,792, and €4,031 in the second
year (P = 0.460). In the 2nd year, costs were signiﬁcantly
reduced in Group 1. This study underlines the importance
of depression for health costs, and suggests that treatment
of depression could be associated with long-term cost
reductions.
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Background
Depressive disorders are the third leading cause of dis-
ability in Europe [1] and lead to considerable costs from
treatment, productivity loss, accidents, and suicides [2]. To
understand the economic impact of depression and to
inform health policy, cost-of-illness studies are important
[3]. In patients starting treatment for depression, long-term
cost analyses are particularly relevant, since the interven-
tion costs may peak in the ﬁrst year, while cost reductions
secondary to clinical improvement may not occur until
subsequent years [4]. Patients responding to depression
treatment have lower costs in the ﬁrst 6–12 months, com-
pared to non-responding patients [5], but there are limited
data on this phenomenon beyond 12-month follow-up [6,
7], and no intervention has been shown to reduce costs
signiﬁcantly compared to a control group beyond
12 months [7–11].
Due to the high prevalence of depression, it is also
important to assess depression costs in different types of
patients and settings. Up to one-half of patients with self-
reported [12] or physician-diagnosed [13] depression use
complementary therapies, but only a few depression cost
analyses have included costs of complementary therapies
[14–16].
An opportunity to study the long-term costs of com-
plementary and conventional treatments for depression as
well as indirect costs was offered by the Anthroposophic
Medicine Outcomes Study (AMOS) [17]. AMOS was a
prospective cohort study of outpatients with various
chronic indications treated by physicians providing
anthroposophic medicine (AM—a complementary therapy
system) in addition to conventional care. The study was
conducted in conjunction with a health beneﬁt program. An
analysis of patients treated for depressive disorder showed
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[18].
Anthroposophic treatment for depression differs from
ordinary treatment in its use of non-verbal artistic and
physical therapies and special AM medications [18].
Similar to recent guideline recommendations [19], con-
ventional antidepressant drugs are not used as initial ther-
apy for mild depression. In cases of severe depression,
however, AM therapies are often combined with antide-
pressants [20]. Similar to conventional care, AM physi-
cians may offer counselling and refer patients for
psychotherapy or, if necessary, for inpatient treatment [18].
One research question of the AMOS study concerned
the cost-of-illness of depression and other chronic diseases
[21]. Here we present a secondary cost analysis from
AMOS, contrasting patients treated for depression, patients
with depressive symptoms treated for another disorder, and
patients without depressive symptoms.
Methods
Objective and design
The objective was to study long-term depression costs in a
German AM outpatient setting from the societal perspec-
tive. For this purpose, we analysed healthcare use and
productivity loss in a prospective cohort of patients starting
AM therapies (AMOS), and calculated direct and indirect
costs. The cost analysis had two main objectives:
1. Comparison of patients treated for depression, patients
with depressive symptoms treated for another disorder,
and patients without depressive symptoms.
2. Comparison of the pre-study year to the 1st and
2nd years after enrolment.
Setting, participants, and therapy
Participating physicians were certiﬁed by the Physicians’
Association for Anthroposophical Medicine in Germany
and had ofﬁce-based practices or worked in outpatient
clinics in Germany. The physicians recruited consecutive
patients starting AM therapy. Patients enrolled in the per-
iod 1 January 1999–31 March 2001 were included in the
present analysis if they fulﬁlled the eligibility criteria.
Inclusion criteria for all patients in this analysis were:
• age 17–70 years;
• starting AM therapy for a disorder of minimum
6 months’ duration (main disorder):
– referral to non-medical therapists (providing AM
art therapy involving painting, drawing, clay
modelling, music or speech exercises; or AM
eurythmy movement exercise therapy; or AM
rhythmical massage therapy);
– or starting AM therapy provided by study physician
(AM-related consultations, AM medication) after
an initial AM-related consultation C30 min.
Further inclusion criteria applied to the three groups
studied:
Patients treated for depression (Group 1)
• Center for Epidemiological Studies Depression Scale,
German version (CES-D) C24 points, which is the cut-
off point for clinically relevant depressive symptoms
[22, 23];
• physician’s diagnosis of main disorder as depression or
depressive symptoms;
• depressed mood plus at least two of the following
depressive core symptoms [symptoms of dysthymic
disorder, according to Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition (DSM-IV)]: poor
appetite or overeating, insomnia or hypersomnia, low
energy or fatigue, low self-esteem, poor concentration or
difﬁcultymakingdecisions,feelingsofhopelessness[24].
Patients with depressive symptoms, treated for another
disorder (Group 2)
• CES-D C 24 points;
• physician’s diagnosis of main disorder is NOT depres-
sion or depressive symptoms.
Patients without depressive symptoms (Group 3)
• CES-D\24 points.
The patients were treated according to the physician’s
discretion.
Outcome measures
The primary outcome was overall health costs, regardless of
diagnosis, in the pre-study year and in the 1st and 2nd study
years.Costsincludeddirecthealthcosts(AMtherapies,non-
AM complementary therapies, physician and dentist visits,
psychotherapy, medication, physiotherapy, occupational
therapy, inpatient hospital and rehabilitation treatment) and
indirect costs (sick-leave compensation, early retirement,
mortality) and were assessed from a societal perspective.
Depressive symptoms were assessed by the CES-D,
ranging from 0 (‘‘no depressive symptoms’’) to 60
(‘‘maximum symptoms’’). Patients document the frequency
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123of 20 symptoms during the last week, from 0 (‘‘rarely or
none of the time & less than 1 day’’) to 3 (‘‘most or all of
the time & 5–7 days’’) [22, 23].
Baseline health status was assessed with the SF-36
Physical Component summary score, the SF-36 Health
Change item [25], disease duration, and disease severity.
Disease severity was assessed by the physicians on a
numerical rating scale [26] from 0 (‘‘not present’’) to 10
(‘‘worst possible’’).
Medical comorbidity was assessed with the Chronic
Disease Score [27]. The Chronic Disease Score is based on
medications used to treat chronic diseases, is a good pre-
dictor of future hospitalisations and health costs [28], and
has been used in a number of cost analyses of depression
[6, 29–31]. We used the original version [27] with 17
medication classes (updated for newer medications [32,
33]), which does not include psychotropic medications and
is not associated with depression or anxiety [27]. The
Chronic Disease Score has a theoretical range of 0–35
points, the upper range requiring intake of 20 different
medications. AMOS study documentation was truncated at
eight medications per patient and observation period,
resulting in a range of 0–17 points.
Resource utilisation included AM therapies, medication,
physician and dentist visits, diagnostic investigations,
psychotherapy, physiotherapy, occupational therapy, and
inpatient hospital and rehabilitation treatment.
Productivity loss included sick-leave, early retirement,
and deaths regardless of the cause of death.
Data collection
All data were documented with questionnaires returned in
sealed envelopes to the study ofﬁce. Physicians documented
name, duration and severity of main disorder, comorbid
disorders, and (Group 1 only) depressive core symptoms; all
other items were documented by patients. Patient responses
were not made available to physicians. Resource use and
productivity loss in the pre-study year were documented at
study enrolment; in the 1st and 2nd study years these items
were documented after 3 months (medication only), and
after 6, 12, 18, and 24 months. Physicians were compen-
sated €40 per included and fully documented patient, while
patients received no compensation.
Data were entered twice by two different individuals into
Microsoft
  Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charite ´, Humboldt University Berlin,
and was conducted according to the Declaration of
Helsinki and International Conference on Harmonisation
Good Clinical Practice guidelines. Written informed con-
sent was obtained from all patients before enrolment.
Data analysis
Data analysis [PASW
  Statistics 17.0 (http://www.spss.
com/statistics/), StatExact
  5.0.3 (http://www.cytel.com/
products/statxact/), S-PLUS
  8.0 (http://www.insightful.com/
products/splus/)] was performed on all patients fulﬁlling the
eligibility criteria.
Resource use and unit costs (Table 1)
Costs were analysed from a societal perspective. For all
resource items except non-AM complementary therapies,
costs were calculated by multiplying resource use by the
unit cost for the respective item. Out-of-pocket expendi-
tures for non-AM complementary therapies were docu-
mented directly.
Unit costs (Table 1) were calculated from average costs
in Germany for the year 2000 (physicians’ and dentists’
fees, medication, hospital, rehabilitation, sick-leave costs
[34, 35]) or from reimbursement fees regulated in health-
care beneﬁt catalogues (AM therapies, diagnostic investi-
gations, psychotherapy, physiotherapy, occupational
therapy [36–38]).
Hospital costs were calculated from average costs in
each German federal state [39]. Physicians’ fees were
calculated from average fees of general practitio-
ners plus 12 specialist categories in the Accounting Data
Record Panel of the Central Research Institute of Ambu-
latory Health Care in Germany [40]. Costs for diagnostic
investigations (X-rays, computer tomography scans,
nuclear magnetic resonance imaging and scintigrams) were
calculated separately [36]. Costs of AM medication (any
medication produced by the pharmaceutical companies
Abnoba Arzneimittel, Pforzheim, Germany; Helixor Heil-
mittel, Rosenfeld Germany; Wala Heilmittel, Bad Boll/
Eckwa ¨lden, Germany; and Weleda, Arlesheim, Switzer-
land) were calculated from average costs in 51 different
price groups. Costs of other medications were calculated
from national average costs in 86 Anatomical Therapeutic
Chemical Classiﬁcation Index subgroups [41].
Costs of productivity loss included costs for sick-leave,
early retirement, and deaths. Costs for sick-leave and early
retirement were calculated from national average gender-
speciﬁc earnings for civil servants, salaried employees, and
wage earners (100% compensation for days 1–42, 70%
compensation thereafter) [35]. Mortality costs (4.3% of all
costs of productivity loss) were calculated with the same
method.
Unless otherwise stated, costs were not discounted.
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Missing data for resource items and for expenditures for
non-AM complementary therapies consisted of: (1) missing
data for items in available questionnaires (0.5% of items),
and (2) missing follow-up questionnaires (14.7% of
administered questionnaires). Missing data for (1) were
replaced by the group mean value for the respective item
and follow-up period. Missing data for (2) were replaced
with the last value carried forward—the last value referring
to the preceding 6-month documentation period (missing
values for the 0–6-month follow-up period were replaced
with 50% of the corresponding value in the pre-study year).
In an alternative analysis, missing data for (2) were
replaced using multiple imputations [42]; results differed
little from the main analysis, with maximum differences in
unadjusted total costs of 5, 5, and 7% in Groups 1, 2, and 3,
respectively.
Missing data also occurred for two variables used in the
adjusted costs analyses: missing values for baseline disease
severity (physician documentation: n = 6 values missing
in 487 patients) were replaced by the respective values for
a corresponding outcome documented by patients
(Symptom Score [17]). Missing values for baseline SF-36
scores (n = 6 values missing out of 3,896 values) were
replaced by the mean value in the respective patient group
(1, 2 or 3).
Unadjusted analyses
For total costs, bootstrap means with bias-corrected and
accelerated (BCa) bootstrap 95% conﬁdence intervals
(95% CI) were calculated, using 2,000 replications per
analysis [43]. For all other unadjusted analyses, two
independent samples were compared with Mann–Whitney-
U-Test and Fisher’s Exact Test for continuous and dichot-
omous data, respectively; three independent samples were
compared with the Kruskal–Wallis test and the Cochran–
Armitage trend test. Median differences with 95% CI were
estimated according to Hodges and Lehmann [44]. All
Table 1 Cost calculation
Health service category Measurement unit Categories/subgroups analysed
separately
Unit cost
(range) in Euros
Source
Anthroposophic therapies Therapy session Eurythmy, art, rhythmical
massage
19.9–32.2 Health insurance
company data
Anthroposophic medication Daily dose Price groups (51) 0.1–5.2 Manufacturer’s
price lists
Non-anthroposophic
complementary therapies
Euro (out-of-pocket
expenditures)
Not applicable
Physician visit Visit Specialist categories (12) 12.3–28.6 [40]
Dentist visit Visit (excluding dental prosthesis) 62.4 [34]
Psychotherapy Therapy session 56.1 [36]
Diagnostic investigation Investigation X-rays, computer tomography
scans, nuclear magnetic
resonance imaging,
scintigrams
17.4–200.3 [36]
Non-anthroposophic
medication
Daily dose Anatomical Therapeutic
Chemical Classiﬁcation
Index groups (86)
0.1–37.1 [41]
Physiotherapy Therapy session Remedial gymnastics, exercise
therapy, massage, fango
packs, aerothermotherapy,
other
5.7–13.7 [37]
Occupational therapy Therapy session 24.9 [38]
Inpatient hospitalisation Day German Federal states (16) 271.0–411.0 [39]
Inpatient rehabilitation Day 58.0 Health insurance
company data
Sick-leave, early
retirement, mortality
Day Days 1–42 vs days[42/self-
employed, civil servants,
salaried employees, wage
earners, unemployed/males
vs females
41.5–113.1 [35]
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123unadjusted analyses were considered explorative, with
signiﬁcance criteria P\0.05 and 95% CI not including 0.
Adjusted analyses
Total costs in the three groups and 3 years were adjusted
for socio-demographic characteristics, comorbidity, and
baseline health status. Since the three groups were deﬁned
by their depression status, we did not adjust for depressive
symptoms (baseline CES-D) and included only those
independent variables that showed low or minimal corre-
lation to baseline CES-D, deﬁned as Spearman-Rho\0.3.
The following 11 variables were included in the main
analysis: patient group (1, 2 or 3), age, gender, education,
engagement in economic activity, living in the former
German Democratic Republic, disease duration, Chronic
Disease Score, baseline disease severity, baseline SF-36
Physical Component, and baseline SF-36 Health Change.
In an alternative analysis, stricter criteria for inclusion of
independent variables were used, with a correlation to
baseline CES-D\0.2 instead of\0.3. This lead to exclu-
sion of 1 of the 11 variables (SF-36 Health change) from
the models, although the overall results were very similar.
In another alternative analysis, the impact of a 12th
variable, household income, was explored. This variable
was available for only 84% of patients, was not a signiﬁ-
cant predictor in any models, and was not included in the
main analysis.
The following adjustment models were used:
• In a preliminary analysis, general linear models with
repeated measures were used, with the natural loga-
rithm of total costs as dependent variable and study
year as within-subject variable. Results were similar to
results of the other adjusted analyses but are of lesser
utility due to the use of the logarithm of costs [45].
Results are therefore not shown.
• For the main analysis, generalised linear modelling was
used to build three models with total costs in the pre-
study year, 1st, and 2nd years, respectively, as depen-
dent variable [46–48]. Since costs were highly skewed,
a gamma distribution with a log link was used. The
inﬂuence of the 11 independent variables on the costs
was analysed in a main effects model, using a robust
covariance matrix, estimation of scale parameters by
the maximum likelihood method, testing for model
effects and between-group differences with Wald chi-
square statistics, and estimation of marginal means with
Wald type 95% CI. (An alternative model included the
interaction of age and gender, which was a signiﬁcant
predictor in the pre-study year only. Results were
otherwise changed only minimally, and this interaction
was not used in the main analysis). Multiple
comparisons between Groups 1, 2 and 3 were corrected
with the sequential Bonferroni method. For all 11
variables in the models the variance inﬂation factors
were\1.2, suggesting that multicollinearity was not a
problem. The model for the 1st year showed a good ﬁt
with a ratio deviance/df of 1.024, while the models for
the pre-study year and 2nd year showed signs of some
overdispersion with ratios deviance/df of 1.387 and
1.685, respectively. Scatter plots of standardised devi-
ance residuals, Pearson residuals, and Likelihood
residuals vs predicted mean revealed 2–4 outliers for
each model. According to Cook’s distance and leverage
values, 0–2 of these outliers were potentially inﬂuential
for each model, respectively. Data inspection showed
no evidence of documentation errors of the cost values
for the identiﬁed outliers. Moreover, the exclusion of
outliers from the models led to only minimal changes
(with the exception of one change in the 1st year; see
Results section). Hence all outliers were retained in the
main analysis.
• A supplementary fourth model was built using general-
ised estimating equations with average total costs across
the 3 years as dependent variable, study year as within-
subject variable, and model speciﬁcations analogous to
the three generalised linear models described above.
Sensitivity analyses
Two sensitivity analyses were performed, for the following
reasons:
1. A previous sensitivity analysis of cost units in the
AMOS study [17] had identiﬁed one item for which
uncertainty in the assumptions could have a relevant
impact on costs: inpatient hospital treatment. Hospital
costs will vary according to hospital specialisation,
which was not documented in the study; therefore
average costs across hospital specialties were used.
Costs in German psychiatric and neurological hospitals
are lower (average €203 per day) than in general
hospitals (€309). Accordingly, hospital costs in
depressed patients (Groups 1 and 2) were analysed
under the extreme assumption that 100% of hospital
days were spent in psychiatric or neurological hospi-
tals (instead of 7%—the German average) [35, 49].
2. The inclusion criteria for Group 1 required fulﬁlment
of all depression criteria, which can be considered a
narrow deﬁnition, as AM physicians may treat patients
for depressive symptoms regardless of diagnostic
criteria. Accordingly, total costs were analysed using
less restrictive criteria for Group 1, including all
patients aged 17–70 years starting therapy for depres-
sive symptoms.
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Participating physicians
A total of 104 AM-certiﬁed physicians enrolled patients
into the study; these physicians did not differ signiﬁcantly
from AM-certiﬁed physicians in Germany not enrolling
patients (n = 258) regarding age (mean ± SD: 45.9 ± 7.0
vs 48.3 ± 8.1 years), gender (54.8 vs 65.1% males), num-
ber of years in practice (18.0 ± 7.4 vs 20.2 ± 9.2 years)
or the proportion of physicians working in primary care
(86.5 vs 84.4%).
Patient recruitment and follow-up
From 1 January 1999 to 31 March 2001, a total of 783
patients aged 17–70 years starting AM therapy were
screened for inclusion. Of these, 487 patients were
included in the present analysis (Fig. 1). Of the 296
patients who were not included, 206 were potentially
eligible. These potentially eligible patients did not differ
from included patients in terms of gender, disease dura-
tion or baseline disease severity. The potentially eligible
patients not included were an average of 6.3 years (95%
CI 3.5–9.2 years) younger than included patients
(P\0.001).
A total of 81.9% (n = 399/487) of patients were
enrolled by general practitioners, 6.8% by internists, 5.7%
by gynaecologists, 3.1% by psychiatrists, and 2.5% by
other specialists. The physicians’ settings were primary
care practices (87.5% of patients, n = 426/487), referral
practices (8.4%), and outpatient clinics (4.1%).
The last patient follow-up ensued on 30 April 2003.
A total of 97.5% (n = 475/487) of patients returned at least
one follow-up questionnaire; return rates were 93.2, 91.4,
86.2, 80.1, and 75.4% after 3, 6, 12, 18, and 24 months,
respectively. The 487 patients were administered a total of
2,435 follow-up questionnaires, of which 2,076 (85.3%)
questionnaires were returned. Return rates did not differ
signiﬁcantly between Groups 1, 2, and 3 at any follow-up
Group 1:  n = 81 
Patients treated for 
depressive disorder 
Excluded:  n = 296 
Group 2:  n = 103 
Patients with 
depressive symptoms, 
treated for another 
disorder  
Group 3:  n = 303 
Patients without 
depressive symptoms 
Not eligible: n = 90 
  Duration of main disorder < 6 months: n = 86 
  Another eligibility criterion not fulfilled: n = 4 
Potentially eligible: n = 206 
  Patients’ and physician’s baseline questionnaire 
dated > 30 days apart: n = 58 
  Patients’ baseline questionnaire missing: n = 57 
  Physician’s baseline questionnaire missing: n = 28 
  Baseline CES-D not evaluable: n = 24 
  No informed consent: n = 8 
 Other  reasons:  n  =  31 
Screened for inclusion:  n = 783 
Included:  n = 487 
Fig. 1 Patient recruitment. CES-D Center for Epidemiological Studies Depression Scale, German version
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123point. Respondents and non-respondents of the 24-month
follow-up questionnaire did not differ signiﬁcantly
regarding age, gender, disease duration, baseline CES-D or
total health costs in the pre-study year.
Baseline characteristics
Patients were recruited from 15 of 16 German federal
states. The three groups did not differ signiﬁcantly
regarding demographics, disease duration or comorbidity.
The groups differed regarding disease severity, SF-36
Physical Component, SF-36 Health Change, and, by nature
of the inclusion criteria, by the main diagnosis and baseline
CES-D (Table 2).
In Group 1, the duration of the depressive disorder was
6–11 months in 9% (n = 7/81) of patients, 12–23 months
in 9%, and C2 years in 83%. Of the patients in Group 1,
23% (n = 19/81) had a history of inpatient psychiatric
treatment.
Change in depressive symptoms
From baseline to 24-month follow-up, CES-D improved by
median 15.9 points (95% CI 12.5–19.0, P\0.001) in
Group 1, by 12.8 points (95% CI 9.5–16.0, P\0.001) in
Group 2, and by 3.0 points (95% CI 2.0–4.0, P\0.001)
in Group 3.
Resource use and productivity loss
Psychotherapy use and the number of visits to physicians
and dentists differed signiﬁcantly between the three groups
at all time periods, with lower use in Group 3. Three items
differed signiﬁcantly between the three groups in one time
period each (see Table 3), while the remaining items did
not differ between the groups in any period.
In all three groups, AM therapies and AM medication
use increased signiﬁcantly in the 1st year compared to the
pre-study year (P\0.001 for all comparisons); AM ther-
apies also increased in the 2nd year in all three groups.
These increases are a consequence of the study inclusion
criterion of patients starting AM treatment. Compared to
the pre-study year, the number of inpatient hospital days
decreased signiﬁcantly in the 1st year in Group 3
(P = 0.007) and in the 2nd year in Group 1 (P = 0.024),
the number of inpatient rehabilitation days was decreased
in the 1st (P = 0.016) and 2nd years (P = 0.003) in Group
1, the number of diagnostic investigations was reduced in
the 1st year in Group 2 (P = 0.002), and the number of
patients with early retirement was increased in the 2nd year
in Group 3 (P = 0.008). No other signiﬁcant pre-post
changes occurred in any group or time period.
Costs
Unadjusted analyses
Unadjusted total costs and costs for all analysed items are
presented in Table 4. In the pre-study year, costs in Group
1 (bootstrap mean €6,739) were 41% higher than in Group
2( €4,763) and 88% higher than in group 3 (€3,588). In
each group (1, 2, and 3), total costs in the pre-study year
were compared to total costs in the 1st and 2nd years,
respectively. One signiﬁcant change was observed: In the
2nd year, costs were reduced signiﬁcantly from the pre-
study year in Group 1 (bootstrap mean difference €1,808;
95% CI €1,110–€4,858). No other signiﬁcant pre-post
changes were observed in any group or period. The
cost reduction in the second year in Group 1 could be
attributed largely to a reduction in inpatient hospitalisation
(from €3,006 to €1,015) and long-term sick-leave (from
€1,038 to €442).
Among the cost items analysed, hospital costs and sick-
leave costs were the largest contributors to total costs in all
groups and periods, together amounting to an average of
51% of total costs across the 3 years. Hospital costs
amounted to an average of 26% of total costs (range: 14%
of costs in Group 2 in the 1st study year to 45% of costs in
Group 1 in the pre-study year) and sick-leave costs
amounted to an average of 25% (range: 22% of costs in
Groups 1 and 3 in the 1st year to 33% of costs in Group 2
in the pre-study year). Costs for conventional outpatient
treatment (physician and dentist visits, psychotherapy,
medication, physiotherapy, occupational therapy) amoun-
ted to 25% of all costs, while costs for complementary
treatment amounted to 11% (AM therapies: 7%, non-AM
complementary therapies: 4%).
Cost distribution was highly skewed in all groups and
periods; in Group 1, the four most ‘‘expensive’’ patients in
each period (5% of 81 patients) caused 34, 41, and 32% of
costs in the pre-study year, 1st, and 2nd years, respectively.
In depressed patients (Groups 1 ? 2), the correlation
between baseline CES-D and total costs in the pre-study
year and 1st year, respectively, was calculated. Correla-
tions were low (Spearman-Rho 0.11 or lower) and not
signiﬁcant (P = 0.151 or higher).
Adjusted analyses
The 11 independent variables were analysed in four sepa-
rate models for the pre-study year, 1st year, 2nd year, and
across all 3 years, respectively (Table 5). Two variables
(disease severity, SF-36 Physical Component) were sig-
niﬁcant predictors for costs in all four models—higher
costs being predicted by higher disease severity and by
lower scores on the SF-36 Physical Component. One
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Item Group 1 (n = 81) Group 2 (n = 103) Group 3 (n = 303) P-value
Recruited in primary care (n, %) 73 90% 90 87% 263 87% 0.490
Female gender (n, %) 71 88% 83 81% 239 79% 0.093
Age, years (mean ± SD) 43.1 ±9.4 42.2 ±10.9 43.9 ±11.5 0.471
Education [27]( n,% ) 0.679
Low (level 1) 5 7% 13 16% 42 18%
Intermediate (level 2) 45 63% 45 54% 105 44%
High (level 3) 21 30% 25 30% 92 38%
Living in former German Democratic
Republic
17/81 21% 12/103 12% 53/303 18% 0.827
Engagement in economic activity 46 57% 56 54% 161 53% 0.560
Net family income\900 € per month (n,
%)
11/65 17% 12/89 13% 36/255 14% 0.653
Main disorder (International Statistical
Classiﬁcation of Diseases and Related
Health Problems, 10th Revision: n,% )
\0.001
a
C00-D48 Neoplasms 0 0% 7 7% 18 6%
E00-E90 Endocrine, nutritional and
metabolic diseases
0 0% 5 5% 10 3%
F00-F99 Mental and behavioural
disorders
81 100% 11 11% 66 22%
G00-G99 Diseases of the nervous
system
0 0% 13 13% 23 8%
J00-J99 Diseases of the respiratory
system
0 0% 4 4% 25 8%
K00-K93 Diseases of the digestive
system
0 0% 6 6% 12 4%
L00-L99 Diseases of the skin and
subcutaneous tissue
0 0% 6 6% 14 5%
M00-M99 Diseases of the
musculoskeletal system and connective
tissue
0 0% 29 28% 80 26%
N00-N99 Diseases of the genitourinary
system
0 0% 5 5% 21 7%
Other diagnosis chapters (\3% in all
groups, respectively)
0 0% 18 17% 34 11%
Main or comorbid disorder
F30-F39 Affective disorders 81 100% 26 25% 61 20% \0.001
F00-F99 Mental and behavioural
disorders
81 100% 47 46% 111 37% \0.001
Disease duration, years (median,
interquartile range)
5.0 2.3–10.0 6.0 2.0–19.0 5.0 1.5–10.0 0.134
Disease severity (0–10, mean ± SD) 6.9 ±1.4 6.8 ±1.7 6.3 ±1.8 0.003
Chronic Disease Score (0–17,
mean ± SD)
0.51 ±0.90 0.66 ±1.49 0.60 ±1.33 0.517
Center for Epidemiological Studies
Depression Scale, German version
(0–60, mean ± SD)
34.4 ±8.0 31.4 ±6.6 13.7 ±5.9 \0.001
SF-36 Physical Component summary
(mean ± SD)
44.6 ±9.7 40.9 ±10.8 43.6 ±10.8 0.026
SF-36 Health Change (1: ‘‘much better
now than one year ago’’; 5: ‘‘much
worse now than one year ago’’)
3.44 ±1.04 3.53 ±1.04 2.97 ±1.06 \0.001
a Fisher–Freeman–Halton Test
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123variable (patient group) was signiﬁcant in all models
except the 2nd year. Four variables (SF-36 Health Change,
Chronic Disease Score, gender, engagement in economic
activity) were signiﬁcant in the pre-study year only. The
remaining four variables (living in the former German
Democratic Republic, disease duration, age, education)
were not signiﬁcant predictors in any model. Removing
these four variables from all models—or removing all non-
signiﬁcant variables in each model—affected results only
minimally, thus all 11 variables were retained in all four
models. Estimated marginal means for total costs are pre-
sented in Table 6 and Fig. 2:
• In the pre-study year, costs in Group 1 (estimated
marginal mean €7,129) were 63% higher than in Group
2( €4,371) and 102% higher than in group 3 (€3,532).
Cost differences in the pre-study year were signiﬁcant
between Groups 1 and 2 (mean difference €2,758, 95%
CI €67 to €5,449, P = 0.043) and Groups 1 and 3 (mean
difference €3,597, 95% CI €775 to €6,490, P = 0.007),
but not between Groups 2 and 3 (P = 0.180).
• In the 1st study year, costs in Group 1 (€6,029) were
71% higher than in Group 2 (€3,522) and 80% higher
than in Group 3 (€3,353). No between-group differences
were signiﬁcant in the 1st year, although group assign-
ment was a signiﬁcant predictor (P = 0.019). However,
when two potentially inﬂuential outliers were removed
from the model of the 1st year, cost differences between
Groups 1 and 3 became signiﬁcant (P = 0.032).
Table 5 Adjusted analyses:
model effects. GZLM
Generalised linear models, GEE
generalised estimating
equations
a P-values are based on Wald
chi-square statistics and indicate
if the variable is a signiﬁcant
predictor in the model
Year (analysis) 0 (GZLM) 1 (GZLM) 2 (GZLM) 0–1–2 (GEE)
Independent variables P-value
a P-value P-value P-value
Intercept \0.001 \0.001 \0.001 \0.001
Patient group (1, 2 or 3) \0.001 0.019 0.400 0.004
SF-36 Physical Component
Summary at baseline
\0.001 \0.001 \0.001 \0.001
Disease severity at baseline 0.031 0.016 \0.001 \0.001
SF-36 Health Change at baseline 0.009 0.763 0.098 0.196
Chronic Disease Score 0.015 0.657 0.497 0.458
Gender 0.031 0.818 0.468 0.209
Engagement in economic activity 0.043 0.275 0.098 0.070
Living in former German
Democratic Republic
0.135 0.504 0.436 0.500
Disease duration 0.665 0.501 0.839 0.960
Age 0.842 0.946 0.888 0.866
Education 0.869 0.615 0.141 0.364
Table 6 Adjusted analyses: estimated marginal means for total costs (€). P-values are based on Wald chi-square statistics and indicate if
between-group differences are signiﬁcant
Year (analysis) 0 (GZLM) 1 (GZLM) 2 (GZLM) 0–1–2 (GEE)
Group Mean 95% CI
a Mean 95% CI
a Mean 95% CI
a Mean 95% CI
a
Group 1 7,129 4,770 to 9,489 6,029 3,689 to 8,369 4,929 3,156 to 6,702 6,069 4,301 to 7,837
Group 2 4,371 3,180 to 5,563 3,522 2,748 to 4,296 3,792 2,621 to 4,963 3,880 3,145 to 4,614
Group 3 3,532 2,812 to 4,251 3,353 2,782 to 3,924 4,031 3,136 to 4,927 3,691 3,081 to 4,301
Group 1 vs 2 vs 3 P = 0.008 P = 0.083 P = 0.460 P = 0.026
Groups 2 ? 3 3,734 3,052 to 4,417 3,391 2,873 to 3,908 3,986 3,165 to 4,808 3,748 3,222 to 4,275
Group 1 minus Group 2 2,758 67 to 5,449 2,507 -220 to 5,234 1,137 -1,082 to 3,356 2,190 199 to 4,181
P = 0.043
b P = 0.079
b P = 0.659
b P = 0.027
b
Group 1 minus Group 3 3,597 775 to 6,490 2,676 -200 to 5,552 897 -1,132 to 2,927 2,378 266 to 4,490
P = 0.007
b P = 0.078
b P = 0.659
b P = 0.021
b
Group 1 minus Groups 2 ? 3 3,350 1,112 to 5,588 2,619 298 to 4,939 964 -650 to 2,578 2,338 648 to 4,027
P = 0.003 P = 0.027 P = 0.242 P = 0.007
a Wald type 95% conﬁdence interval
b Corrected for multiple comparisons with the sequential Bonferroni method
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123• In the 2nd study year, costs in Group 1 (€4,929) were
30% higher than in Group 2 (€3,792) and 22% higher
than in Group 3 (€4,031). No between-group differ-
ences were signiﬁcant in the 2nd year.
• Costs across all 3 years differed signiﬁcantly between
Groups 1 and 2 (P = 0.027) and 1 and 3 (P = 0.021),
but not between Groups 2 and 3 (P = 0.669; Table 6).
Since costs in Groups 2 and 3 did not differ signiﬁcantly
in any year, the analyses were repeated comparing Group 1
to Groups 2 ? 3 (Table 6). The resulting models were very
similar to the main models, with signiﬁcant between-group
differences in the pre-study year (P = 0.003), 1st year
(P = 0.027), and across all 3 years (P = 0.007), but not in
the 2nd year (P = 0.242).
Compared to unadjusted total costs, adjusted costs were
lower in all years in Groups 2 and 3 (range from 2% lower
in Group 3 in the pre-study year to 25% lower in Group 2
in the 1st year), while adjusted costs in Group 1 were 6%
higher, 12% lower, and 0% higher than unadjusted costs in
the pre-study year, 1st, and 2nd years, respectively.
Sensitivity analyses
In the ﬁrst sensitivity analysis, unadjusted hospital costs in
Groups 1 and 2 were calculated on the basis of average
costs of neurological and psychiatric hospitals in Germany,
instead of average costs for all hospitals. Compared to the
main analysis, total costs in Group 1 were reduced by 13%
(€901), 12% (€798), and 7% (€321) in the pre-study year,
1st, and 2nd study years, respectively; while costs in Group
2 were reduced by 11% (€533), 5% (€228), and 6% (€274),
respectively (P = 0.002 or lower for all comparisons).
In the second analysis, the eligibility criteria for Group 1
(main analysis: n = 81) were widened to include all
AMOS patients aged 17–70 years starting therapy for
depressive symptoms (n = 133, of which n = 36 patients
were from Group 3). Compared to the main analysis,
unadjusted total costs in Group 1 were reduced by 8%
(€554, P = 0.268) and 13% (€903, P = 0.617) in the pre-
study year and 1st year, respectively, and increased by 4%
(€216) in the 2nd year (P = 0.860).
Comparison to another primary care depression sample
in Germany
Unadjusted healthcare costs in Group 1 (90% primary care)
were compared to corresponding costs in a German pri-
mary care patient cohort starting treatment-as-usual for a
depressive disorder [50]. For the purposes of comparabil-
ity, the comparison was restricted to cost items that were
analysed in both studies (outpatient treatment, medication,
inpatient hospital treatment, and rehabilitation; in Group 1
also AM therapies and medications). The comparison
shows a similar order of magnitude and distribution of
costs in both patient groups (Fig. 3).
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Fig. 2 Adjusted total health costs per patient and year. Estimated
marginal means and 95% conﬁdence intervals (CI) after adjustment
for socio-demographic characteristics, comorbidity and baseline
health status (see text for details). Group 1: patients treated for
depression; Group 2: patients treated for another disorder, with
depressive symptoms; Group 3: patients treated for another disorder,
without depressive symptoms
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Fig. 3 Healthcare costs in the 1st year in Group 1 and in a subgroup
of the Salize Study [50]. Group 1: Patients treated for depression
(n = 81). Costs of 1st study year (2000) were discounted by ?5%.
Salize subgroup: Primary care patients (n = 89), costs in year 2001.
Outpatient treatment: physician visits, diagnostic examinations,
psychotherapy, physiotherapy, occupational therapy; in Group 1 also
anthroposophic therapies and medications
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123Discussion
Major ﬁndings
We have analysed costs of healthcare and productivity
loss in three consecutive years in 487 German adult out-
patients starting complementary treatment (AM) for
chronic disease. In the year preceding study enrolment,
costs in patients treated for depressive disorder (Group 1)
were twice as high as costs in non-depressed patients
(Group 3), and 63% higher than in patients with depres-
sive symptoms treated for another disorder (Group 2).
Compared to the pre-study year, costs were signiﬁcantly
decreased in the second study year in Group 1, while costs
in Groups 2 and 3 showed little change. An average of
half of total costs were caused by inpatient hospitalisation
and sick-leave, while conventional and complementary
outpatient treatment amounted to 25 and 11% of total
costs, respectively.
Strengths and limitations
To our knowledge, this is the ﬁrst cost analysis comparing
primary care patients treated for depression with depressed
patients treated for another disorder and with non-depres-
sed patients. It is also one of very few depression analyses
providing annual cost data for 2 or 3 consecutive years [6,
10,51].Furtherstrengthsofthisstudyincludehighfollow-up
rates and the wide range of cost domains assessed. The
healthcare cost domains analysed in this study amount to
87% of healthcare expenditures of the German statutory
health system: physician and dentist services, psychother-
apy, physiotherapy, occupational therapy, medication,
inpatient treatment, sick-leave compensation [34] as well
as out-of-pocket expenditures for complementary thera-
pies. Healthcare costs for dentures, medical appliances,
nursing, patient transport, and health prevention programs
(13% of expenditures in Germany) were not documented in
the study and could not be analysed. Our analysis of
indirect costs included sick-leave costs, costs from early
retirement, and deaths, while reduced productivity on the
workplace was not documented and could not be analysed.
Also not analysed were intangible costs from suffering and
from reduced quality of life in patients or relatives.
Intangible costs of depression are difﬁcult to quantify, and
were not assessed in any studies included in a recent sys-
tematic review of cost-of-illness studies of depression [3].
Since depressive symptoms (and quality of life, data not
shown) improved during the 2-year follow-up in all groups,
intangible costs would be expected to decrease, not to
increase. Therefore, the inclusion of intangible costs would
not have changed the direction of cost reduction observed
in Group 1.
We did not attempt to separate depression-related
treatment costs from other treatment costs. Due to the high
level of comorbidity in depression, our approach of ana-
lysing total healthcare costs may be more appropriate and
has been used more extensively than analyses of depres-
sion-related costs only [3].
In the main analyses, costs were not discounted. Since
all costs except costs of non-AM complementary therapies
were calculated by multiplying resource use with unit
costs, the cost differences from the pre-study year in the 1st
and 2nd years in each group reﬂect differences in resource
use and productivity loss only, and not inﬂation. Costs of
non-AM complementary therapies were documented
directly and were also not discounted. However, since
these costs amounted to only 4% of total costs, discounting
would have had only minimal effects on the total costs.
Group 1 in this analysis consisted of adult patients
treated for depression of at least 6 months’ duration.
Patients were recruited by physicians offering routine care,
and structured psychiatric interviews to assess all criteria
for depression according to DSM-IV or ICD-10 (Interna-
tional Statistical Classiﬁcation of Diseases and Related
Health Problems, 10th Revision) were not feasible, which
limits diagnostic comparability with other studies. How-
ever, all patients in Group 1 fulﬁlled the DSM-IV core
symptom criteria for dysthymic disorder and 83% of
patients fulﬁlled the additional criterion of at least 2 years
symptom duration.
Since the study had a long recruitment period, the study
physicians were not able to participate throughout the
period and to screen and enrol all eligible patients (criteria:
see Methods). For a different subset of patients from the
AMOS project (patients referred to AM therapies for any
chronic indication), it was estimated that physicians
enrolled every fourth eligible patient [18]. This selection
could affect results if physicians were able to predict
therapy response and if they preferentially screened and
enrolled such patients for whom they expected a particu-
larly favourable outcome. In this case one would expect the
degree of selection (the proportion of eligible vs enrolled
patients) to correlate positively with clinical outcomes.
That was not the case, the correlation was almost zero
(-0.04).This analysis[18]doesnotsuggest thatphysicians’
screening of eligible patients was affected by selection
bias. Nevertheless, selection bias affecting costs cannot be
ruled out.
Another issue is the validity of the methods used to
discriminate between the three groups: Groups 1 and 2
differed in the physician’s decision to start treatment for
depression vs another disorder. From the physician’s
perspective this distinction is highly relevant, and it has
been used in a number of depression cost analyses [15, 29,
52–57]. In addition, all Group 1 patients fulﬁlled core
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the distinction between Groups 1 and 2 was associated
with large cost differences in the pre-study year and 1st
year (63 and 71% higher in Group 1 in the pre-study year
and 1st year, respectively). Groups 2 and 3 differed by the
cut-off point for ‘‘relevant depressive symptoms’’ on
the CES-D, German version [23]. The cut-off point for the
original English CES-D version has been used to deﬁne
depression in several cost analyses [30, 58]. The cut-off
value for the German version (24 points) is one standard
deviation above the average score in the German popu-
lation and is a highly sensitive marker for depressive
symptoms, insofar as 94% of patients with a DSM-III-R
diagnosis of an acute depressive episode but only 17% of
the general population will have elevated CES-D scores.
On the other hand, the speciﬁcity of high CES-D scores
for a depression diagnosis is low [23]. In our analysis, the
distinction between Groups 2 and 3 was associated with
modest and non-signiﬁcant costs differences (24 and 5%
higher in Group 2 in the pre-study year and 1st year,
respectively). Groups 1 and 3 differed regarding the
physician’s decision to start treatment for depressive
symptoms (100 vs 12% of patients) and our criteria for
depression (100 vs 0%). These criteria included the
CES-D cut-off value (see above) and the core criteria for
DSM-IV dysthymic disorder [24]. In our analysis, this
distinction was associated with the largest cost differences
(102 and 80% higher in Group 1 in the pre-study year and
1st year, respectively).
A limitation of the study documentation of inpatient
hospitalisation is that hospital specialisation was not
recorded. German psychiatric and neurological hospitals
have average 33% lower costs than general hospitals.
Accordingly, we performed an extreme-scenario sensitivity
analysis, assuming all hospital days in depressed patients
(Groups 1 and 2) were spent in psychiatric or neurological
hospitals. This resulted in only modest reductions of total
costs (range 5–13% for all time periods).
Like most depression cost analyses conducted outside
the United States [3], our study was based on patient self-
reporting of resource use. All resource items were docu-
mented over 3 years and continuous diary-keeping was not
feasible. Therefore, patient documentation of use during
the preceding 12 months (at study enrolment) and pre-
ceding 6 months (at 6-, 12-, 18-, and 24-month follow-up)
might be affected by recall bias. Since patient recall of
resource use declines over time with a net tendency
towards under-reporting [59], under-reporting is more
likely for the 12-month pre-study period than for the
shorter periods after study enrolment. Therefore, cost
reductions from the pre-study year to subsequent years
might be larger than reported (and cost increases may be
lower than reported).
Cost comparisons between the three groups were
adjusted for ten potentially relevant variables pertaining to
socio-demographics, comorbidity, and baseline health sta-
tus. Four of these variables were not signiﬁcant predictors
in any models, and of the remaining six variables, only
three measures of baseline health status (disease severity,
SF 36 Physical Component, SF-36 Health Change) differed
signiﬁcantly between the groups. Our models are of course,
like all statistical adjustment models, imperfect represen-
tations of reality [46]; they do not prove causality, and
residual confounding cannot be ruled out. Furthermore, the
conﬁdence intervals for unadjusted (Table 4) as well as
adjusted (Table 6) cost estimates were relatively wide,
particularly in Group 1. This may be due to the skewed cost
distribution in all three groups, and a relatively modest
sample size for the analysis of skewed data in Group 1 [60].
Among the three main models in the present analysis, the
best model ﬁt was observed for the 1st study year, while the
models for the pre-study year and the 2nd year showed
signs of some overdispersion. This ﬁnding could have
several possible explanations: as noted above, the longer
documentation period for resource use in the pre-study year
could lead to more recall bias and more errors in resource
documentation for this period. Also, since most of the
signiﬁcant predictors in the cost models referred to the
baseline status, predictors could have a more direct rela-
tionship to costs in the ensuing 1st year than to costs in the
pre-study year and in the 2nd year.
Agreement with other studies, and interpretation
The patients treated for depression in this study (Group 1)
differed from other depression cohorts in two aspects: at
enrolment, 100% of patients in Group 1 started artistic or
complementary therapies (AM), combined with antide-
pressants and/or psychotherapy in 45% of patients [18]. In
other treated depression cohorts, 100% of patients usually
start treatment with antidepressants and/or psychotherapy,
while up to 50% of subjects with depression reportedly use
complementary therapies [12, 13]. In Group 1, comple-
mentary treatment (AM and non-AM) amounted to 12% of
all costs in the 1st year, while conventional outpatient
treatment amounted to 22%, and inpatient hospital treat-
ment amounted to 35% of costs. A few other depression
cost studies have included costs for complementary treat-
ment [14–16], but none allow for direct comparison to our
study, as these costs were either not presented separately
[14, 16] or because the only costs for complementary
treatment included were costs for spinal manipulation [15],
which is classiﬁed as conventional treatment in Germany.
The costs of complementary treatment for depression
in this study (12% of total costs and 18% of treatment costs
in the 1st year) suggest that depression cost analyses in
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should account for the costs of complementary treatment.
Another difference to other studies was observed regarding
the female-to-male ratio, which was much larger in Group
1 with 90% primary care patients (7.1/1.0) than in other
German primary care depression cohorts (1.3–3.0/1.0) [61–
65]. Possibly, more women than men with depression
might be motivated to engage in artistic or complementary
therapies. Otherwise, patients in Group 1 were recruited
from all but one German federal states and resembled other
primary care depression cohorts regarding symptom
severity and functional impairment [18]. Nevertheless,
study results might not be generalisable to men and to
patients receiving conventional care only.
Healthcare costs in the 1st study year in Group 1 were
similar to corresponding costs in another German primary
care depression cohort [50]. The relative contribution of
outpatient, hospital, and sick-leave costs in this study as
well as the skewed cost distribution are also similar to
ﬁndings from other studies [3, 16, 56, 66].
In our study, adjusted costs in patients with depression
(Group 1) were twice as high as costs in patients without
depression (Group 3) in the pre-study year and 80% higher
in the 1st year. This large difference is in accordance with
ﬁndings from several other studies with follow-up periods
between 6 and 12 months [52, 54, 55, 67, 68].
Among study patients with relevant depressive symp-
toms, those starting treatment for chronic depression
(Group 1) had higher costs than patients starting treatment
for another chronic disorder (Group 2). The differences
were large in the pre-study year and 1st year (63 and 71%,
respectively) and were signiﬁcant in the pre-study year, but
were not signiﬁcant in the 1st year except if outliers were
removed from the analysis. It is difﬁcult to explain this
difference by differences in baseline CES-D scores, since
baseline CES-D differed by only 10% or 3.0 points (34.4
and 31.4 points in Groups 1 and 2, respectively), and since
there was no signiﬁcant correlation between baseline CES-
D and costs in these two groups. Notably, all patients in
Group 1 had at least three core depression symptoms at
baseline, while fulﬁlment of this criterion was not docu-
mented for Group 2. At baseline, a physician’s diagnosis of
depression (ICD-10 F30-39) was documented in 100% and
25% of patients in Groups 1 and 2, respectively, while
physicians referred to new therapy for depression in 100%
and 0% of patients, respectively. Possibly, in depressed
patients, the physician’s decision to initiate new therapy for
depression is an independent marker for high costs. We are
not aware of other cost studies comparing depressed pri-
mary care patients starting treatment either for depression
or for another disorder.
In our study, costs of patients treated for depression
(Group 1) in the 2nd study year were decreased by 27%
(unadjusted) respectively 31% (adjusted), compared to the
pre-study year, and reduced by 28 and 18%, respectively,
compared to the 1st year. We are aware of three other
depression cost analyses providing cost data for at least 2
consecutive years [6, 10, 51]: in 290 primary care patients
starting antidepressant therapy for major depression,
health-care costs were analysed according to clinical status
after 12 months, whereby 41% of patients had undergone
remission, 47% were improved, and 12% had persistent
depression. Compared to the 1st year, costs in the 2nd year
were reduced by 48% and 33% in improved and remitted
patients, respectively, while costs in patients with persis-
tent depression were increased by 169% [6]. This would
correspond to a 26% cost reduction in the whole sample. In
a randomised trial of systematic depression treatment for
329 patients with diabetes and coexisting major depression,
costs for outpatient treatment in the 2nd year were reduced
by 6% in the intervention group and increased by 12% in a
usual care control group, compared to the 1st year [10]. In
492 subjects in a health maintenance organisation with
high healthcare costs in 2 consecutive years, direct costs in
the 3rd year were increased by 5% in depressed subjects
and reduced by 21% in non-depressed subjects, compared
to the 1st year [51].
The cost reduction in Group 1 could be attributed lar-
gely to a reduction in hospital costs and long-term sick-
leave. The reduction in resource use was paralleled by an
improvement in depressive symptoms and health status
[18] and might thus be related to the complementary and
conventional therapies used. Since this study is a com-
parison by diagnosis in treated patients without an
untreated control group, one has to consider other causes
for these changes, such as natural recovery, regression to
the mean, and secular trends: for improvement in symp-
toms, regression to the mean due to sample truncation of
Group 1 (CES-D C 24 points at inclusion) or due to
symptom ﬂuctuation and preferential self-selection to
therapy and study inclusion at symptom peaks is a possible
explanation [18, 69]. However, these phenomena relate to
symptoms not costs, and baseline symptoms (CES-D) did
not correlate with costs. Moreover, when Group 1 was
reanalysed without truncation (second sensitivity analysis,
with extension of eligibility criteria to include patients with
baseline CES-D scores\24 points) costs were comparable
to costs in the main analysis. Altogether, regression to the
mean cannot be ruled out but seems unlikely as a cause of
the cost reduction in Group 1.
The cost reduction in Group 1 cannot be explained by
secular trends towards a reduction in inpatient hospital
days and long-term sick-leave during the study (1999–
2003). In this period, the average number of hospital
days per person-year in Germany decreased by only
0.21 days (from 2.07 to 1.86 days) [70]. This reduction of
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1230.11 days per 2 years corresponds to only 3% of the
observed reduction of 8.26 days per 2 years (from pre-
study year to 2nd year: from 10.37 to 3.42 days) in Group
1. In the same period, the annual number of sick-leave
days paid by the statutory health insurance (sick-leave
beyond 42 days) was reduced by 0.35 days (from
5.23 to 4.88 days) [71], i.e. by 0.18 days per 2 years,
corresponding to only 3% of the reduction in Group 1 of
12.13 days (from 29.24 to 17.11 days).
Conclusions
This study in a complementary outpatient setting under-
lines the importance of depression for health costs and
suggests that treatment of depression could be associated
with long-term reduction of costs.
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